Product Images Dutasteride

This appears to be a graph showing the change in AUA-ST Score from baseline in a randomized, double-blind, placebo-controlled trials pool. The score ranges from 0 to 35, and the graph displays data across 24 months of treatment with either Placebo or Dutasteride.*

This is a graph showing the percentage of subjects who developed acute urinary retention during a 24-month period in a randomized, double-blind, placebo-controlled trial. The x-axis shows the months of treatment, and the y-axis shows the percentage of patients. The blue line represents the placebo group, and the orange line represents the dutasteride group. The table shows the number of events and the number of patients at risk in each group for each time point.*

The given text represents a figure that shows the number of subjects that had surgery for benign prostatic hyperplasia over a 24-month period in a randomized, double-blind, and placebo-controlled trial. The figure includes four time points - six, twelve, eighteen, and twenty-four months of treatment. The number of events cumulatively increases with each time point for both the placebo and Dutasteride groups. At twenty-four months, the cumulative number of events was 89 for the placebo group and 47 for the Dutasteride group. The total number of subjects at risk at each time point is also provided for both groups.*

The text describes a figure showing the percentage change in prostate volume from baseline in randomized, double-blind and placebo-controlled trials pooled. The figure consists of a graph with results recorded over a period of up to 24 months of treatment. The treatment groups were given either placebo or dutasteride, and the number of participants in each group is also provided.*

The image shows a graph titled "International Prostate Symptom Score Change from Baseline over a 48-Month Period" from a CombAT trial. The graph displays the percentage change in symptom score over time for three groups: Dutasteride + tamsulosin (n=1575), Dutasteride 0.5 mg (n=1592), and Tamsulosin 0.4 mg (n=1582). It appears that the combination therapy group had the greatest reduction in symptoms over the 48-month period.*

The text is describing a graph showing the change in Qmax from baseline over a 24-month period in a trial. The trial was randomized, double-blind, and parallel-group (CombAT Trial). The vertical axis appears to show the mean change from baseline, while the horizontal axis shows the time in months. There are three lines shown on the graph, labeled "A& Dutasteride + Tamsulodn," "Diastaride 0.5mg," and "Emadosind dmg."*

The table shows the adverse reactions reported during a 24-month period of a randomized, double-blind, placebo-controlled trial where Dutasteride was given to one group and the other group a placebo. Adverse reactions that were reported in more than 1% of subjects and more frequently in the Dutasteride group are specified. These adverse reactions include impotence, decreased libido, ejaculation disorders, and breast disorders. Sexual adverse reactions associated with dutasteride treatment may persist even after discontinuation, but the role of dutasteride in such persistence is unknown. Breast tenderness and enlargement are included in breast disorders.*

The given text shows a table of adverse reactions reported over a period of 43 months in different groups receiving either mono or combination therapies with Dutasteride or Tamsulosin, and the onset time of these reactions. The table also includes the percentage of subjects experiencing adverse reactions, including ejaculation disorders, impotence, decreased libido, breast disorders, and dizziness. The combination group showed higher incidence rates of these reactions than other groups. The text provides a detailed description of adverse reactions and their occurrence, which may assist healthcare professionals in monitoring and managing patients on these medications.*

This appears to be a label of a medication named "Dutasteride" with a strength of "0.5mg". The medication is in the form of yellow oval capsules and packaged by "Bryant Ranck Prepack Bunbauk". The label also indicates that the medication is similar to "Avodart" and is to be stored at room temperature. The label contains various product information like batch number, manufacturing date, and an NDC number.*